NCT00002099View on ClinicalTrials.gov

Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

PHASE2UnknownINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Lentinan

DRUG

Didanosine

Trial Locations (1)

92102

HIV Research Group, San Diego

Sponsors

Lead Sponsor

AJI Pharma USA
All Listed Sponsors
lead

AJI Pharma USA

INDUSTRY

NCT00002099 - Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients | Biotech Hunter | Biotech Hunter